MedTrace Logo

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

NCT00827255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2019-04-25

Study results available
· View outcomes & findings →

Summary

The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

Conditions

Interventions

DRUG

Cyclosporine Ophthalmic Emulsion 0.05%

One drop two times a day approximately 12 hours apart

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-06-30
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827255 on ClinicalTrials.gov